• AAPL 192.32
  • TSLA 239.37
  • AMZN 144.52
  • BTC-USD 43327.1016
  • ETH-USD 2242.6631
  • EURUSD 1.0766
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. US /
  3. IPSEY.US

Ipsen SA ADR (IPSEY PINK) stock market data APIs

$28.063 0.26(0.9%) as of December 6, 2023

Ipsen SA ADR Financial Data Overview

27.8
28.063
-
28.063
27.51
25.4963-34.338
9 277 M
21.0606
331 M
3 282 M
0
0.0116
0.587
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'IPSEY',
Type: 'Common Stock',
Name: 'Ipsen SA ADR',
Exchange: 'PINK',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG000PZ4WW4',
ISIN: NULL,
CUSIP: NULL,
CIK: NULL,
EmployerIdNumber: NULL,
FiscalYearEnd: 'December',
IPODate: NULL,
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Drug Manufacturers - Specialty & Generic',
GicSector: NULL,
GicGroup: NULL,
GicIndustry: NULL,
GicSubIndustry: NULL,
HomeCategory: NULL,
IsDelisted: false,
}

Ipsen SA ADR Fundamental Data is available in our Financial Data APIs

  • Net Revenue 3 282 M
  • EBITDA 1 064 M
  • Earnings Per Share 1.32
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $49.99 See full price
Get sample
of Fundamental API Data

Get Ipsen SA ADR Earnings via APIs

  • Latest Release 2023-10-26
  • EPS/Forecast 0

Get Ipsen SA ADR End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Ipsen SA ADR latest news via APIs

Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC

Ipsen Pharma New Drug Application granted priority review with PDUFA date set for June 10, 2024 European Medicines Agency (EMA) has also validated the Marketing Authorization Application (MAA) for e...

Capital Markets Day 2023 - Ipsen outlines next phase of growth & transformation and provides new mid-term outlook

Ipsen Pharma PARIS, FRANCE, 7 December 2023 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, today holds its Capital Markets Day in London, U.K. “Ipsen has...
Still have any questions?

Or need any other data for equities, funds or ETFs? Send us an email.

support@eodhistoricaldata.com